ReShape Operating Income from 2010 to 2025
| RSLS Stock | USD 0.65 0.01 1.52% |
Operating Income | First Reported 2005-03-31 | Previous Quarter -2.1 M | Current Value -1.8 M | Quarterly Volatility 5.1 M |
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 22.2 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.19, Dividend Yield of 0.0 or PTB Ratio of 0.24. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
ReShape | Operating Income |
Latest ReShape Lifesciences' Operating Income Growth Pattern
Below is the plot of the Operating Income of ReShape Lifesciences over the last few years. Operating Income is the amount of profit realized from ReShape Lifesciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ReShape Lifesciences is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. ReShape Lifesciences' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
ReShape Operating Income Regression Statistics
| Arithmetic Mean | (21,591,813) | |
| Geometric Mean | 18,621,907 | |
| Coefficient Of Variation | (41.70) | |
| Mean Deviation | 7,207,240 | |
| Median | (22,795,627) | |
| Standard Deviation | 9,003,520 | |
| Sample Variance | 81.1T | |
| Range | 36.6M | |
| R-Value | 0.09 | |
| Mean Square Error | 86.1T | |
| R-Squared | 0.01 | |
| Significance | 0.73 | |
| Slope | 175,774 | |
| Total Sum of Squares | 1216T |
ReShape Operating Income History
Other Fundumenentals of ReShape Lifesciences
ReShape Lifesciences Operating Income component correlations
Click cells to compare fundamentals
About ReShape Lifesciences Financial Statements
ReShape Lifesciences shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -13.2 M | -13.8 M | |
| Non Operating Income Net Other | -6.6 M | -6.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.